Trials / Completed
CompletedNCT02076399
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib disodium | Fostamatinib (100 mg PO bid or 150 mg PO bid) |
| DRUG | Placebo | Placebo tablet PO bid (morning and evening) over the course of 24 weeks |
Timeline
- Start date
- 2014-07-14
- Primary completion
- 2016-04-21
- Completion
- 2016-04-21
- First posted
- 2014-03-03
- Last updated
- 2019-02-12
- Results posted
- 2019-01-11
Locations
52 sites across 8 countries: United States, Australia, Canada, Denmark, Hungary, Italy, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT02076399. Inclusion in this directory is not an endorsement.